Form 4: BeOne Medicines Global Head of R&D Reports Sale of Shares for Tax Withholding

BeOne Medicines Ltd.'s Global Head of R&D, Wang Lai, reported a sale of 1,028 American Depositary Shares (ADS) at $260 per share, primarily to cover tax obligations related to the vesting of restricted share units.

Summary

• Wang Lai, Global Head of R&D at BeOne Medicines Ltd. (ONC), filed a Form 4 reporting changes in beneficial ownership.
• On June 23, 2025, Mr. Lai directly disposed of 1,028 American Depositary Shares (ADS) at a price of $260 per ADS.
• This sale was executed pursuant to a mandatory tax withholding provision in his restricted share unit (RSU) award agreement, in connection with the vesting of a previously granted RSU award.
• The RSU award vests 1/4th on each anniversary of June 22, 2022, subject to continued service, with unvested securities subject to accelerated vesting upon certain termination events.
• Following the transaction, Mr. Lai directly holds 1,023,529 Ordinary Shares and indirectly holds 731,965 Ordinary Shares through Wang Holdings LLC.
• Mr. Lai also has an indirect economic interest in an indeterminable portion of RMB Shares held by the RMB Shares Employee Participation Plan, to which he contributed RMB10 million, but disclaims Section 16 beneficial ownership over these shares.
• Each American Depositary Share represents 13 Ordinary Shares.
• The RMB Shares Employee Participation Plan previously purchased 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at an initial public offering price of RMB192.6 per RMB Share (approximately $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, it's for a routine and expected reason (tax withholding on RSU vesting), which implies the executive is receiving compensation and continuing service. It does not suggest a negative outlook on the company.

Positives

• The transaction is a result of restricted share unit (RSU) vesting, indicating that the executive has met performance or tenure requirements, which can be a positive sign of executive retention and company performance.
• The sale was for tax withholding purposes, which is a common and often pre-planned event for executives receiving equity compensation, rather than a discretionary sale indicating a lack of confidence.

Negatives

• Any insider sale, even for tax purposes, can be perceived negatively by some investors as it reduces the executive's direct equity stake in the company.

Risks

• The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent of his pecuniary interest, which could lead to less transparency regarding his full economic exposure to those shares.
• Future vesting events of restricted share units may lead to additional sales for tax withholding purposes, potentially increasing the float of shares.

Future Outlook

The document indicates future vesting events for the restricted share unit award, with 1/4th of the securities vesting on each anniversary of June 22, 2022, subject to continued service. This implies potential future tax-related sales or increased beneficial ownership for the executive.

Management Comments

• The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person.

Industry Context

Insider transactions, particularly those related to equity compensation vesting and subsequent tax withholding, are common across all industries, including the pharmaceutical and biotechnology sectors. Such sales are generally considered routine and do not typically signal a change in management's outlook on the company's prospects, especially when pre-planned under Rule 10b5-1(c).

Comparison to Industry Standards

• The practice of selling shares to cover tax obligations upon the vesting of restricted stock units is a standard and widely accepted mechanism for managing equity compensation in publicly traded companies across various industries, including biotech and pharma.
• Many executives at comparable companies like Pfizer, Merck, or Johnson & Johnson regularly report similar tax-related sales of vested equity awards, often pre-arranged through 10b5-1 plans to avoid accusations of trading on inside information.
• The specific price of $260 per ADS is unique to BeOne Medicines Ltd. and its current market valuation, but the *mechanism* of the sale is consistent with global benchmarks for executive compensation and tax compliance.

Related Party Transactions

• The indirect ownership of 731,965 Ordinary Shares through Wang Holdings LLC, a limited liability company whose interests are owned by the Reporting Person, his spouse, and a trust for their benefit, constitutes a related party holding.
• The Reporting Person's participation in the RMB Shares Employee Participation Plan, to which he contributed RMB10 million, represents an indirect related party economic interest, although he disclaims Section 16 beneficial ownership.

Stakeholder Impact

• Shareholders: The sale of shares for tax withholding is a routine event and is unlikely to have a significant impact on the share price or shareholder value, especially given its pre-planned nature.
• Employees: The vesting of RSUs and the associated tax sale are part of the company's executive compensation structure, which can be seen as a positive for employee retention and motivation at the executive level.

Next Steps

• Future vesting dates for the restricted share unit award will occur on each anniversary of June 22, 2022, potentially leading to further share releases or tax-related sales.

Key Dates

Keywords

SEC Form 4, Insider Transaction, Stock Sale, Restricted Share Units, Tax Withholding, BeOne Medicines, ONC, Executive Compensation, Beneficial Ownership, Equity Compensation